Clinical Trials Logo

PFS clinical trials

View clinical trials related to PFS.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05267366 Recruiting - PFS Clinical Trials

Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC

Start date: February 1, 2022
Phase: Phase 2
Study type: Interventional

In recent years, immunotherapy has emerged as a form of treatment that can lead to robust responses in a subset of patients. PD-1 inhibitor plus chemotherapy showed prolonged survival in NSCLC by the study of KEYNOTE 024, KEYNOTE 189 etc. Thus, this study combines immunotherapeutic agent PD-1 inhibitor with an ant-angiogenic agent, bevacizumab, and double platinum therapy (carboplatin/cisplatin and pemetrexed).

NCT ID: NCT05267288 Recruiting - PFS Clinical Trials

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

There is no report afatinib plus bevacizumab in the treatment of EGFR G719X, S768I, and L861Q single or compond mutation of metastatic non-small-cell lung cancer (NSCLC). The purpose of this study is to study afatinib combined with bevacizumab in the management of it.

NCT ID: NCT04520035 Recruiting - PFS Clinical Trials

Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell

Start date: August 1, 2020
Phase: Phase 2
Study type: Interventional

A prospective, single arm, single center, phase II clinical trial of neoadjuvant chemotherapy with camrelizumab in locally advanced esophageal squamous cell,to evaluate the progression free survival

NCT ID: NCT04425187 Recruiting - PFS Clinical Trials

Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC

Start date: June 8, 2020
Phase: Phase 2
Study type: Interventional

To compare the efficacy and safety of gefitinib combined with bevacizumab and gefitinib in the treatment of L858R positive mutation in exon 21 of EGFR gene in advanced NSCLC.

NCT ID: NCT02629718 Recruiting - Quality of Life Clinical Trials

Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer

SYSGO-003
Start date: December 2015
Phase: Phase 3
Study type: Interventional

To clarify the potential benefits of NACT before radical surgery(RS), we perform a phase III, randomised controlled trial to compare NACT plus RS with RS alone in patients with stages IB2 and IIA2 cervical cancer.